Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Monday 26.02.2024 at 12:00 PM CET
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K38/00 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/250209LACTOFERRIN FOR ORAL USE WITH ANTIVIRAL ACTION
WO 17.12.2020
Int.Class A61K 38/40
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
40Transferrins, e.g. lactoferrins, ovotransferrins
Appl.No PCT/IB2020/059695 Applicant SOFAR S.P.A. Inventor BIFFI, Andrea
The present invention relates to a composition comprising lactoferrin for oral use as an antiviral, preferably for use in the treatment of viral infections of the respiratory system and of symptoms or disorders deriving from, or relating to, said viral infections, preferably SARS-coronavirus viral infections (e.g. COVID-19).
2.WO/2021/181261LACTOFERRIN FOR ORAL INHALATION USE FOR THE TREATMENT OF A DISEASE CAUSED BY A SARS-CORONA VIRUS
WO 16.09.2021
Int.Class A61K 38/40
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
40Transferrins, e.g. lactoferrins, ovotransferrins
Appl.No PCT/IB2021/051941 Applicant SOFAR S.P.A. Inventor BIFFI, Andrea
The present invention relates to a composition comprising lactoferrin for inhalation use in the treatment of viral infections of the respiratory system, and related symptoms or disorders, caused by a SARS- coronavirus (e.g. COVID-19 disease). In addition, the present invention relates to a device for the administration - through the inhalation route - of said composition comprising lactoferrin and the use thereof in said methods for the treatment of viral infections.
3.WO/2022/167675MOLECULES FOR USE IN THE TREATMENT AND/OR PREVENTION OF COVID-19
WO 11.08.2022
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/EP2022/052944 Applicant HUMANITAS MIRASOLE S.P.A. Inventor MANTOVANI, Alberto
The present invention relates to a molecule for use in the treatment and/or prevention of viral infections caused by highly pathogenic coronaviruses, including Severe Acute Respiratory syndrome Coronavirus 2 (SARS-CoV-2), or variants thereof, Severe Acute Respiratory syndrome Coronavirus ((SARS)-CoV) and sarbecoviruses, said molecule being a mannose binding lectin (MBL) polypeptide, or a functional fragment, derivative, mutein or variant thereof, or an homologue having a percentage of identity with MBL polypeptide of at least 50, 60, 70, 80 or 90%, preferably for use in the treatment and/or prevention of 2019 Coronavirus disease (COVID-19).
4.20220387561TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS INFECTION WITH KLOTHO
US 08.12.2022
Int.Class A61K 38/47
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
46Hydrolases (3)
47acting on glycosyl compounds (3.2), e.g. cellulases, lactases
Appl.No 17702719 Applicant Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Inventor Román Federico Macaya Hayes

Methods and compositions for treating a severe acute respiratory syndrome-related coronavirus (SARS-CoV) infection in a subject in need are provided. In some aspects, a therapeutically effective amount of a Klotho polypeptide and/or a Klotho polynucleotide encoding a Klotho polypeptide is administered to the subject. In some other aspects, the subject is treated with a first therapy when the subject has diminished Klotho activity, and with a second therapy when the subject does not have diminished Klotho activity. Diminished Klotho activity is determined by comparing the amount of Klotho protein in a blood sample from the subject to a predetermined threshold. In particular, methods and compositions for treating SARS-CoV-2 infection are provided.

5.WO/2022/008971TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS INFECTION WITH KLOTHO
WO 13.01.2022
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/IB2021/000460 Applicant COSTA RICAN SOCIAL SECURITY FUND / CAJA COSTARRICENSE DE SEGURO SOCIAL (CCSS) Inventor MACAYA HAYES, Roman, Federico
Methods and compositions for treating a severe acute respiratory syndrome- related coronavirus (SARS-CoV) infection in a subject in need are provided. In some aspects, a therapeutically effective amount of a Klotho polypeptide and/or a Klotho polynucleotide encoding a Klotho polypeptide is administered to the subject. In some other aspects, the subject is treated with a first therapy when the subject has diminished Klotho activity, and with a second therapy when the subject does not have diminished Klotho activity. Diminished Klotho activity is determined by comparing the amount of Klotho protein in a blood sample from the subject to a predetermined threshold. In particular, methods and compositions for treating SARS-CoV-2 infection are provided.
6.WO/2022/204431PREVENTION AND TREATMENT OF CORONAVIRUS INFECTION
WO 29.09.2022
Int.Class C07K 7/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
06having 5 to 11 amino acids
Appl.No PCT/US2022/021791 Applicant ANAVEX LIFE SCIENCES CORP. Inventor MISSLING, Christopher U.
Provided herein are compositions comprising one or more diphenyl compounds, such as ANAVEX 1066, or its metabolites, or isomers, or salts, for use in treating symptoms of, or preventing an infection by a coronavirus, particularly an infection caused by a SARS-CoV-2 virus.
7.WO/2021/198999EPITOPE-BASED VACCINES FOR TREATMENT OF CORONAVIRUS ASSOCIATED DISEASES
WO 07.10.2021
Int.Class C07K 11/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
11Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
Appl.No PCT/IB2021/052781 Applicant AXON NEUROSCIENCE SE Inventor ZILKA, Norbert
The disclosures described herein relate to polypeptides, antibodies, and compositions for use in the treatment and diagnosis of severe acute respiratory syndrome (SARS) coronavirus-associated diseases or disorders. Provided are new immunogenic compositions related to SARS CoV2 S protein and method of preventing and/or treating severe acute respiratory syndrome and other SARS-CoV-related disease, including COVID-19. Also provided are diagnostic reagents for the detection of SARS virus, SARS Cov2 S protein, a complex of SARS Cov2 S protein and ACE2, and/or severe acute respiratory syndrome or other SARS-CoV-related disease.
8.WO/2023/170187INHIBITION OF INTRACELLULAR PATHOGEN UPTAKE BY INHIBITORS OF THE IKK-α/NIK COMPLEX
WO 14.09.2023
Int.Class A61K 31/4418
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4418having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
Appl.No PCT/EP2023/055949 Applicant TECHNISCHE UNIVERSITÄT MÜNCHEN Inventor PICHLMAIR, Andreas
The invention refers to an inhibitor of the IκB kinase-α (IKK-α)/ NF-κB-inducing kinase (NIK) complex for use in preventing or treating infection, in particular viral or bacterial infection in a cell and/or subject, in particular for preventing or treating SARS-CoV-2 infection in a subject and/or for use in preventing or treating coronavirus disease 2019 (COVID-19) in a subject. Corresponding pharmaceutical compositions are also contemplated.
9.WO/2023/278461CXC CHEMOKINE AGONISTS AND ANTAGONISTS IN COVID-19 DISEASE AND DIAGNOSTIC ASSAYS
WO 05.01.2023
Int.Class A61K 38/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
Appl.No PCT/US2022/035333 Applicant UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION Inventor WILLIS, Monte S.
Methods of treating a disease, disorder or syndrome associated with a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (such as COVID-19) in a subject by administering one or more C-X-C chemokine receptor 3 (CXCR3) antagonist peptides are described. Diagnostic methods for enhancing replication of SARS-CoV-2 in cultured cells and/or detecting the presence of SARS-CoV-2 in cultured cells by contacting the cells with a CXCR3 agonist peptide are also described.
10.WO/2021/254667COBICISTAT FOR PREVENTION AND/OR TREATMENT OF CORONAVIRUS INFECTIONS
WO 23.12.2021
Int.Class A61K 31/5377
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
5377not condensed and containing further heterocyclic rings, e.g. timolol
Appl.No PCT/EP2021/055621 Applicant UNIVERSITÄT HEIDELBERG Inventor FARES, Mohamed, Omar
The present invention relates to cobicistat and its derivatives or prodrugs for use in the prophylaxis and/or treatment of severe acute respiratory syndrome coronavirus type 2 (SARS- CoV-2) infection, severe acute respiratory syndrome coronavirus (SARS-CoV) infection and/or Middle East respiratory syndrome coronavirus (MERS-CoV) infection. The present invention further relates to methods of prevention and/or treatment of SARS-CoV-2 infection.